Chemotherapy and autophagy-mediated cell death in pancreatic cancer cells

被引:24
作者
Ropolo, Alejandro [1 ]
Bagnes, Claudia I. [2 ]
Molejon, Maria I. [1 ]
Lo Re, Andrea [1 ]
Boggio, Veronica [1 ]
Gonzalez, Claudio D. [2 ]
Vaccaro, Maria I. [1 ]
机构
[1] Univ Buenos Aires, Dept Pathophysiol, Sch Pharm & Biochem, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Sch Med, Dept Pharmacol, Buenos Aires, DF, Argentina
关键词
Autophagy; Pancreatic cancer; Chemotherapeutic drugs; UP-REGULATION; TUMOR-CELLS; TISSUE TRANSGLUTAMINASE; OXIDATIVE STRESS; DRUG-RESISTANT; HYPOXIA; BNIP3; TARGET; FAMILY; APOPTOSIS;
D O I
10.1016/j.pan.2011.11.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Autophagy is an evolutionarily preserved degradation process of cytoplasmic cellular constituents and plays important physiological roles in human health and disease. It has been proposed that autophagy plays an important role both in tumor progression and in promotion of cancer cell death, although the molecular mechanisms responsible for this dual action of autophagy in cancer have not been elucidated. Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies with 2-3% five-year survival rate. Its poor prognosis has been attributed to the lack of specific symptoms and early detection tools, and its relatively refractory to traditional cytotoxic agents and radiotherapy. Experimental evidence pointed at autophagy as a pancreatic cancer cell mechanism to survive under adverse environmental conditions, or as a defective programmed cell death mechanism that favors pancreatic cancer cell resistance to treatment. Here, we consider several phenotypical alterations that have been related to increase or decrease the autophagic process in pancreatic tumor cells. We specially review autophagy as a cell death mechanism in response to chemotherapeutic drugs. Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 67 条
[1]   AGE-RAGE system and carcinogenesis [J].
Abe, Riichiro ;
Yamagishi, Sho-ichi .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) :940-945
[2]   Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death [J].
Abe, T ;
Toyota, M ;
Suzuki, H ;
Murai, M ;
Akino, K ;
Ueno, M ;
Nojima, M ;
Yawata, A ;
Miyakawa, H ;
Suga, T ;
Ito, H ;
Endo, T ;
Tokino, T ;
Hinoda, Y ;
Imai, K .
JOURNAL OF GASTROENTEROLOGY, 2005, 40 (05) :504-510
[3]   Tissue transglutaminase inhibits autophagy in pancreatic cancer cells [J].
Akar, Ugur ;
Ozpolat, Bulent ;
Mehta, Kapil ;
Fok, Jansina ;
Kondo, Yasuko ;
Lopez-Berestein, Gabriel .
MOLECULAR CANCER RESEARCH, 2007, 5 (03) :241-249
[4]   S100P promotes pancreatic cancer growth, survival, and invasion [J].
Arumugam, T ;
Simeone, DM ;
Van Golen, K ;
Logsdon, CD .
CLINICAL CANCER RESEARCH, 2005, 11 (15) :5356-5364
[5]   Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3 [J].
Azad, Meghan B. ;
Chen, Yongqiang ;
Henson, Elizabeth S. ;
Cizeau, Jeannick ;
McMillan-Ward, Eileen ;
Israels, Sara J. ;
Gibson, Spencer B. .
AUTOPHAGY, 2008, 4 (02) :195-204
[6]   Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model [J].
Büchler, P ;
Reber, HA ;
Lavey, RS ;
Tomlinson, J ;
Büchler, MW ;
Friess, H ;
Hines, OJ .
JOURNAL OF SURGICAL RESEARCH, 2004, 120 (02) :295-303
[7]   The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death [J].
Burton, T. R. ;
Gibson, S. B. .
CELL DEATH AND DIFFERENTIATION, 2009, 16 (04) :515-523
[8]   Sodium/potasium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides:: a new paradigm for development of anti-breast cancer drugs? [J].
Chen, JQ ;
Contreras, RG ;
Wang, R ;
Fernandez, SV ;
Shoshani, L ;
Russo, IH ;
Cereijido, M ;
Russo, J .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 96 (01) :1-15
[9]   Role and regulation of autophagy in cancer [J].
Chen, Ning ;
Karantza-Wadsworth, Vassiliki .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2009, 1793 (09) :1516-1523
[10]   Randomized phase III TRIAL COMPARING FOLFIRINOX (F: 5FU/LEUCOVORIN [LV], IRINOTECAN [1], AND OXALIPLATIN [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial [J].
Conroy, T. ;
Desseigne, F. ;
Ychou, M. ;
Ducreux, M. ;
Bouche, O. ;
Guimbaud, R. ;
Becouarn, Y. ;
Montoto-Grillot, C. ;
Gourgou-Bourgade, S. ;
Adenis, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)